Efficacy of Tolvaptan in acute heart failure patients with preserved left ventricular ejection fraction
Phase of Trial: Phase IV
Latest Information Update: 25 Apr 2018
Price : $35 *
At a glance
- Drugs Tolvaptan (Primary)
- Indications Cardiac oedema; Heart failure
- Focus Therapeutic Use
- 16 Feb 2017 Primary endpoint (Incidence of worsening renal function (WRF)) has been met, according to the article published in the Circulation Journal.
- 16 Feb 2017 Status changed from recruiting to completed based on the results published in the Circulation Journal.
- 16 Feb 2017 Results published in the Circulation Journal.